Abiopharma

🔍 Cowan Elvia (Executive)

Company: Vaxcyte, Inc. (PCVX)

Report Date: 2025-08-29

Detailed Transactions and Holdings:

• Acquired 2,810 shares of Common Stock (Direct)
  Date: 2025-09-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 27,205.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 9,743 shares of Stock Option (right to buy) at $30.79 per share (Derivative)
  Date: 2025-08-29 | Code: A | Expires: 2035-08-29 | equity_swap_involved: 0 | shares_owned_after: 9,743.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on March 7, 2026 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
• F2: Includes 289 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.
• F3: 1/48 of shares subject to the option vest on September 29, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.